# OnCo record immunomedics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/immunomedics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "immunomedics" ;
  schema:name "Immunomedics"@en ;
  schema:alternateName "Immunomedics, Inc."@en, "NASDAQ:IMMU"@en ;
  schema:description "Immunomedics developed Trodelvy (sacituzumab govitecan), an antibody that carries chemotherapy to cancer cells carrying a protein called Trop-2, first approved for triple-negative breast cancer. Gilead bought the company in 2020."@en ;
  schema:url <https://onco.cc/companies/immunomedics/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/722830/000110465920104608/tm2030753d1_ex99-1.htm>, <https://www.sec.gov/Archives/edgar/data/722830/000110465920117764/tm2034060-1_8k.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/trop2/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/> .